Fully integrated, pre-clinical stage biotechnology company developing therapeutics for the accessible treatment of psychiatric diseases
Gilgamesh is developing the next generation of central nervous system drugs derived from psychedelics
Diamond Therapeutics develops psilocybin based medicines while mitigating side effects
Myco Systemics' mission is to provide systemic scalable myco-cultivation infrastructure to enable producers to meet the demands of the exploding global mushroom market
Tactogen is a public benefit cooperation whose goal is to make transformative medicines safer, more effective, and more accessible
Mindleap's integration coaches help you to understand and embody the most important parts of your Psychedelic trip, allowing you to create lasting personal transformation.
ATAI is committed to developing more effective and potentially disease-modifying mental health treatments by researching both psychedelic and non-psychedelic compounds.
Universal Ibogaine's mission is to bring proven Ibogaine based clinical treatment protocol to the world and help solve the international opioid crisis
GoodCap is developing effective mushroom-based treatments that open new pathways to a healthier future.
Gwella's focus is on developing transformative consumer brands, products and technologies aimed at elevating people's health and wellbeing.
Lucid News provides informed, honest and transparent journalism that covers the growing integration of psychedelics into society and their broad implications for human wellness.
Orthogonal's mission is to give people access to nature’s most effective health solutions while setting the standard of a new “Farma”: Food as Medicine.
.
A digital media company covering psychedelics and all they intersect with, from healthcare disparities to the climate crisis
.
A life sciences company whose mission is to treat traumatic brain injury and other mental health ailments using psilocybin and other natural therapies.
Awakn Life Sciences is a biotechnology company with clinical operations researching, developing, and delivering psychedelic new chemical entity drugs and therapies to treat Addiction.
Psilera is reimagining psychoactive natural products as building blocks for the next generation of neurological therapeutics.
March 30 - April 2, 2023
JLS Fund’s Lindsay Hoover will be speaking at the Convergence Psychedelics Conference in Los Angeles. She’ll be joined by Hamilton Morris and Dr. Carl Hart, among others. And as a bonus, we’ve created a promo code INSIDERCONV10 (10% off any ticket type).
April 13, 2023
JLS Fund’s Simeon Schnapper will be speaking at the Benzinga Psychedelics Capital Conference in Miami Beach, Florida. The conference, for which Simeon is also a council board member, brings together psychedelics industry leaders and forward thinking investors.
How Awkn is navigating the tough market for investment capital
Psychedelics were the hot topic at the World Economic Forum 2022
How Awkn is navigating the tough market for investment capital
How Awkn is navigating the tough market for investment capital
He was the Canadian head of the world’s largest pot company. His next big bet? A rare fungus worth thousands a kilogram.
Will Psychedelics Continue To Grow In 2021? Jeff Siegel Shares Insights And Strategies As More Companies Go Public
Investors are pouring millions into startups that are developing magic mushrooms as medications for conditions like depression and PTSD
Meet the top 14 psychedelics startups raising the most cash to develop new ways of treating depression, addiction, and more
William Leonard Pickard spoke at a private event
William Leonard Pickard spoke at a private event
William Leonard Pickard spoke at a private event
William Leonard Pickard spoke at an interdisciplinary symposium at Ohio State University on the future of psychedelic research
William Leonard Pickard spoke at the first annual "Psychedelic Science and Spirituality Summit" in Stowe, Vermont
William Leonard Pickard spoke at Horizons Northwest's "Perspectives on Psychedelics" conference
Lindsay Hoover spoke at Horizons: The Psychedelic Business Forum, the largest and longest-running annual gathering of the psychedelic community in the world
Simeon Schnapper spoke on a panel discussing the intersection of psychedelic research, treatments, and investment
Simeon Schnapper on the tensions between philanthropic and for-profit investment, and the challenges and opportunities of this explosive new sector.
Political Importance of Ibogaine Development with Rick Doblin, JLS' Simeon Schnapper, and Daniel Callahan
Simeon Schnapper and Lindsay Hoover discuss investing in the psychedelic space and the developing ecosystem of this emerging industry.
William Leonard Pickard presented at a panel entitled: The Pathway to Federal Acceptance
Lindsay Hoover speaks on Consolidation in the Psychedelics Industry: What to Expect
William Leonard Pickard and Caleb O. Brown discuss promise and pitfalls in taking psychedelic medicine mainstream.
Lindsay Hoover on differentiating opportunities between private & public companies
Jeff Siegel on investing in the future of mental healthcare: psychedelics as an asset class
Simeon Schnapper moderates a panel on addressing mental health through emerging therapies.
Lindsay Hoover of JLS Fund: Psychedelics as Therapeutics: The Contribution of Game Heuristics
Watch Simeon Schnapper on Pysched, the show that explores psychedelics through political, social, and economic perspectives.
Stay up to speed with the world of psychedelics with our weekly updates. Sign up.